BC
SANA icon

Bridgefront Capital’s Sana Biotechnology SANA Stock Holding History

Bridgefront Capital’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10,475
Closed -$63K – 499
2022
Q3 		$63K Buy
+10,475
New +$75.6K 0.06% 288

Other funds holding SANA

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Public Sector Pension Investment Board (PSP Investments)
Public Sector Pension Investment Board (PSP Investments) Montreal, Quebec, Canada $38.7B AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

Bridgefront Capital's SANA Position: Q4 2022 in Review

Bridgefront Capital sold out of Sana Biotechnology (SANA) in Q4 2022, closing a stake of 10,475 shares — an estimated $63K sold.

Bridgefront Capital first reported a position in SANA in Q3 2022 and held it in 1 quarter. The position peaked at $63K in Q3 2022. 119 funds tracked by Wall St. Rank hold SANA as of Q4 2022.

  • Bridgefront Capital reported no remaining Sana Biotechnology position as of Q4 2022 after selling out during the quarter.
  • Bridgefront Capital sold 10,475 Sana Biotechnology shares in Q4 2022, an estimated $63K.
  • Bridgefront Capital first reported a position in Sana Biotechnology in Q3 2022 and held it in 1 quarter.
  • Bridgefront Capital's Sana Biotechnology position peaked at $63K in Q3 2022.
  • 119 funds tracked by Wall St. Rank held Sana Biotechnology as of Q4 2022.

Based on Bridgefront Capital's 13F filing for Q4 2022, filed 15 Feb 2023.